Oric Pharmaceuticals, Inc. (ORIC): Capital Expenditures
$712.0K
Year ended 2025-12-31
$620.0K
Trailing 12 months to 2026-06-30
-30.0%
3-year compound annual growth
+1.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $712.0K | -40.1% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $1.19M | +39.9% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $849.0K | -59.1% | 2025-02-18, From 2023-01-01 |
| 2022-12-31 | $2.08M | +121.3% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $939.0K | +40.8% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $667.0K | -13.2% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $768.0K | +46.3% | 2022-03-21, From 2019-01-01 |
| 2018-12-31 | $525.0K | n/a | 2021-03-23, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $712.0K | -40.1% |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $1.21M | -72.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $670.0K | +230.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $887.0K | -44.4% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $1.05M | +39.0% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $34.0K | -76.1% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $128.0K | +113.3% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $35.0K | -93.3% |
Compare ORIC, ALMS, NKTX, STOK side by side · Screen every company in Pharmaceutical Preparations ↗